. . "Antitumour activity of N-6-substituted PMEDAP derivatives against T-cell lymphoma"@en . . "0250-7005" . . . . "The antitumour activity of four N-6-substituted PMEDAP derivatives, Me2NEt-PMEDAP, allyl-PMEDAP, Me-2-PMEDAP and cypr-PMEDAP, selected on the basis of their in vitro cytostatic activity, was studied in an in vivo model of haematological malignancy of inbred Sprague-Dawley rats. These compounds are believed to serve as the prodrugs of another (phosphonomethoxy) ethyl derivative, PMEG (9-[2-phosphonomethoxy) ethyl] guanine. We compared their toxicity and ability to inhibit tumour development in two different dosage regimes with those of their parent compound PMEDAP, as well with PMEG. The study confirmed the anticancer efficacy of the parental compound PMEDAP. Unlike PMEDAP, its N-6-mono- and disubstituted congeners Me2NEt-PMEDAP, allyl-PMEDAP and Me-2-PMEDAP were less potent or exhibited the same antineoplastic effect as PMEDAP. cypr-PMEDAP significantly decreased the survival of lymphoma-bearing rats due to high toxicity, which was approximately the same as that of PMEG, Therefore, these acyclic nucle" . "Mandys, V\u00E1clav" . "673535" . . "8"^^ . "[2938ACEC1014]" . . "000170276600054" . . "rat; spontaneous lymphoma; PMEDAP derivatives"@en . "1"^^ . "3B" . . . . "Anticancer Research" . "RIV/00216208:11120/01:00003665!RIV12-MSM-11120___" . "GR - \u0158eck\u00E1 republika" . "Antitumour activity of N-6-substituted PMEDAP derivatives against T-cell lymphoma" . "21" . . . . "The antitumour activity of four N-6-substituted PMEDAP derivatives, Me2NEt-PMEDAP, allyl-PMEDAP, Me-2-PMEDAP and cypr-PMEDAP, selected on the basis of their in vitro cytostatic activity, was studied in an in vivo model of haematological malignancy of inbred Sprague-Dawley rats. These compounds are believed to serve as the prodrugs of another (phosphonomethoxy) ethyl derivative, PMEG (9-[2-phosphonomethoxy) ethyl] guanine. We compared their toxicity and ability to inhibit tumour development in two different dosage regimes with those of their parent compound PMEDAP, as well with PMEG. The study confirmed the anticancer efficacy of the parental compound PMEDAP. Unlike PMEDAP, its N-6-mono- and disubstituted congeners Me2NEt-PMEDAP, allyl-PMEDAP and Me-2-PMEDAP were less potent or exhibited the same antineoplastic effect as PMEDAP. cypr-PMEDAP significantly decreased the survival of lymphoma-bearing rats due to high toxicity, which was approximately the same as that of PMEG, Therefore, these acyclic nucle"@en . "5"^^ . "P(GV203/96/K128), P(NL5423), Z(AV0Z4055905), Z(AV0Z5039906), Z(MSM 111200002)" . "Antitumour activity of N-6-substituted PMEDAP derivatives against T-cell lymphoma"@en . "11120" . . . "Antitumour activity of N-6-substituted PMEDAP derivatives against T-cell lymphoma" . . . "Valeri\u00E1nov\u00E1, M." . . "RIV/00216208:11120/01:00003665" .